Post Profile






MS Trust Seeking PPMS Patients’ Views on Ocrevus as It Tries to Obtain British Coverage

Britain’s Multiple Sclerosis Trust is asking patients to help them get the National Health Service to cover Ocrevus (ocrelizumab) as a treatment for primary progressive multiple sclerosis, or PPMS. The key step is trying to persuade the National Institute for Health and Care Excellence to recommend that the health service cover the Genentech therapy. The institute, also known as NICE, is an advisory […] The post MS Trust Seeking PPMS Patients’ Views on Ocrevus as It Tries to Obtain British Coverage appeared first on Multiple Sclerosis News Today.
read more

share

Related Posts


Ocrevus Treatment and Side Effects: What’s Important to Know

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab) is a newly FDA-approved therapy for multiple sclerosis. It can be used to treat two forms of the disease: relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). MORE: Ocrevus approval: A quick cheat s...

Ongoing Ocrevus Trials Seek More Knowledge of Treatment Effects and MS Patients’ Benefits

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab), a recently approved therapy for relapsing and primary progressive multiple sclerosis (MS), is now on the U.S. market, but research into its use is far from over. Several clinical trials, sponsored by Ocrevus’ ...

Genentech to Report on Ocrevus Success in Reducing Disease Progression in Relapsing and Primary Progressive MS at EAN Congress

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab) significantly reduces disease activity and disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive MS (PPMS), according to results of post-hoc analyses of Genentech’s P...

#ACTRIMS2017 – No Evidence of Progression More Likely Among PPMS Patients on Ocrevus

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Genentech’s Ocrevus (ocrelizumab) increased the proportion of patients with no evidence of progression (NEP) in the recently concluded ORATORIO Phase 3 clinical trial in patients with primary progressive multiple sclerosis (PPMS). T...

#ACTRIMS2018 – Relapsing MS Patients With Impaired Vision Improved on Ocrevus, Updated Trial Data Show

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Ocrevus (ocrelizumab) improved vision among relapsing multiple sclerosis (MS) patients who participated in the Phase 3 clinical trials of the treatment, according to updated analyses recently presented at the Americas Committee for ...

Comments


Copyright © 2016 Regator, LLC